Skip to main content
SpringerLink
Log in

Vernakalant

RSD 1235, RSD-1235, RSD1235

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Technology Vision Group LLC. BioPartnering North America. 4th Annual BioPartnering North America: 5 Feb 2006

    Google Scholar 

  2. Cardiome Pharma Corp, Fujisawa Healthcare Inc. Cardiome and Fujisawa sign US$68 million partnership agreement. Media Release: 16 Oct 2003. Available from URL: http://www.cardiome.com

    Google Scholar 

  3. Cardiome Pharma Corp. Cardiome And Astellas Amend Agreement. Media Release: 10 Jul 2006. Available from URL: http://www.cardiome.com

    Google Scholar 

  4. Cardiome Pharma Corp. Cardiome receives US$6 million milestone payment. Media Release: 23 Feb 2005. Available from URL: http://www.cardiome.com

    Google Scholar 

  5. Cardiome Pharma Corporation. Cardiome Reported RSD1235 to Proceed to Phase III Clinical Development. Media Release: 13 May 2003. Available from URL: http://www.cardiome.com

    Google Scholar 

  6. Cardiome Pharma Corp, Fujisawa Healthcare Inc. Cardiome’s pivotal AF study achieves primary endpoint. Media Release: 20 Dec 2004. Available from URL: http://www.cardiome.com

    Google Scholar 

  7. Cardiome Pharma Corp.. Cardiome completes ACT 1 enrolment. Media Release: 12 Oct 2004. Available from URL: http://www.cardiome.com

    Google Scholar 

  8. Cardiome Pharma Corporation. Cardiome initiates cardiac surgery clinical study, revises Phase 3 guidance. Media Release: 29 Mar 2004. Available from URL: http://www.cardiome.com

    Google Scholar 

  9. Cardiome Pharma Corp.. Cardiome Reports Additional Phase 1 Trial Data For Oral RSD1235. Media Release: 5 May 2006. Available from URL: http://www.cardiome.com

    Google Scholar 

  10. Cardiome Pharma Corporation. Third phase 3 study initiated for Cardiome’s atrial arrhythmia product. Media Release: 7 Jul 2004. Available from URL: http://www.cardiome.com

    Google Scholar 

  11. Cardiome Pharma Corp., Astellas Pharma US Inc. Cardiome And Astellas Announce Positive Results From Second Phase 3 Trial. Media Release: 29 Sep 2005. Available from URL: http://www.cardiome.com

    Google Scholar 

  12. Cardiome Pharma Corp, Astellas Pharma US Inc. Cardiome And Astellas Initiate ACT 4 Study. Media Release: 19 Oct 2005. Available from URL: http://www.cardiome.com

    Google Scholar 

  13. Cardiome Pharma Corp.. Cardiome Successfully Completes Second Phase 1 Trial. Media Release: 25 Apr 2005. Available from URL: http://www.cardiome.com

    Google Scholar 

  14. Cardiome Pharma Corp.. Cardiome Successfully Completes RSD1235 Oral Phase 1 Trial. Media Release: 31 Aug 2005. Available from URL: http://www.cardiome.com

  15. Ezrin A, Grant S, Bell G, et al. Safety and pharmacokinetics of RSD1235, a novel atrial fibrillation converting drug, in healthy volunteers. Cardiovascular Drugs and Therapy 16 (Suppl. 1): 49, May 2002

    Google Scholar 

  16. Cardiome Pharma Corp. Cardiome Drug Effective for Heart Patients. Media Release: 3 Sep 2002. Available from URL: http://www.cardiome.com

    Google Scholar 

  17. Roy D, Beatch G, Steill I, et al. RSD1235 rapidly and effectively terminates atrial fibrillation. European Heart Journal 24 (Abstr. Suppl.): 720, Aug–Sep 2003

    Article  Google Scholar 

  18. Pratt C, Roy D, Juul-Møller S, et al. Efficacy and tolerance of RSD1235 in the treatment of atrial fibrillation or atrial flutter: results of a phase III, randomized, placebo-controlled, multicenter trial. Journal of the American College of Cardiology 47 (Suppl. A): 10 (plus oral presentation) abstr. 804-3, No. 4, 21 Feb 2006

    Google Scholar 

  19. Dorian P, Mangat I, Korley V, et al. Electrophysiological properties of an atrial selective antiarrhythmic agent, RSD1235, in humans. Circulation 110 (Suppl.): 461, No. 17, 26 Oct 2004

    Google Scholar 

  20. Dorian P, Mangat I, Korley V, et al. Electrophysiological properties of an atrial selective antiarrhythmic agent, RSD1235, in humans. Canadian Journal of Cardiology 20 (Suppl. D): 198, Oct 2004

    Google Scholar 

  21. Cardiome Pharma Corp. Cardiome Announces Positive Phase 2a Results For Oral RSD1235. Media Release: 13 Sep 2006. Available from URL: http://www.cardiome.com

  22. Cardiome Pharma Corp. Cardiome Announces Interim Phase 2a Results for Oral RSD1235. Media Release: 24 Jul 2006. Available from URL: http://www.cardiome.com

    Google Scholar 

  23. Cardiome Pharma Corp, Fujisawa Healthcare Inc. Cardiome reports additional ACT 1 clinical results. Media Release: 4 Feb 2005. Available from URL: http://www.cardiome.com

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vernakalant. Drugs R D 8, 259–265 (2007). https://doi.org/10.2165/00126839-200708040-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200708040-00007

Keywords

Search

Navigation